Ocaña-Tienda Beatriz, Pérez-Beteta Julián, Romero-Rosales José Antonio, Asenjo Beatriz, Ortiz de Mendivil Ana, Pérez Romasanta Luis Alberto, Albillo Labarra Jose David, Nagib Fátima, Vidal Denis María, Luque Belén, Arana Estanislao, Pérez-García Víctor M
Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
Department of Radiology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
Neurooncol Adv. 2023 Dec 10;6(1):vdad161. doi: 10.1093/noajnl/vdad161. eCollection 2024 Jan-Dec.
The Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) criteria are the gold standard for assessing brain metastases (BMs) treatment response. However, they are limited by their reliance on 1D, despite the routine use of high-resolution T1-weighted MRI scans for BMs, which allows for 3D measurements. Our study aimed to investigate whether volumetric measurements could improve the response assessment in patients with BMs.
We retrospectively evaluated a dataset comprising 783 BMs and analyzed the response of 185 of them from 132 patients who underwent stereotactic radiotherapy between 2007 and 2021 at 5 hospitals. We used T1-weighted MRIs to compute the volume of the lesions. For the volumetric criteria, progressive disease was defined as at least a 30% increase in volume, and partial response was characterized by a 20% volume reduction.
Our study showed that the proposed volumetric criteria outperformed the RANO-BM criteria in several aspects: (1) Evaluating every lesion, while RANO-BM failed to evaluate 9.2% of them. (2) Classifying response effectively in 140 lesions, compared to only 72 lesions classified by RANO-BM. (3) Identifying BM recurrences a median of 3.3 months earlier than RANO-BM criteria.
Our study demonstrates the superiority of volumetric criteria in improving the response assessment of BMs compared to the RANO-BM criteria. Our proposed criteria allow for evaluation of every lesion, regardless of its size or shape, better classification, and enable earlier identification of progressive disease. Volumetric criteria provide a standardized, reliable, and objective tool for assessing treatment response.
神经肿瘤脑转移瘤疗效评估(RANO-BM)标准是评估脑转移瘤(BM)治疗反应的金标准。然而,尽管常规使用高分辨率T1加权MRI扫描来评估BM,其允许进行三维测量,但该标准仍受限于对一维测量的依赖。我们的研究旨在调查体积测量是否能改善BM患者的疗效评估。
我们回顾性评估了一个包含783个BM的数据集,并分析了2007年至2021年间在5家医院接受立体定向放射治疗的132例患者中185个BM的反应。我们使用T1加权MRI计算病变体积。对于体积标准,疾病进展定义为体积至少增加30%,部分缓解的特征是体积减少20%。
我们的研究表明,所提出的体积标准在几个方面优于RANO-BM标准:(1)评估每个病变,而RANO-BM未能评估其中的9.2%。(2)有效分类140个病变的反应,相比之下,RANO-BM仅分类72个病变。(3)比RANO-BM标准提前中位3.3个月识别BM复发。
我们的研究证明了体积标准在改善BM疗效评估方面优于RANO-BM标准。我们提出的标准允许评估每个病变,无论其大小或形状如何,能更好地分类,并能更早地识别疾病进展。体积标准为评估治疗反应提供了一个标准化、可靠和客观的工具。